The Rezaie Laboratory focuses on research related to the microbiome, gastrointestinal (GI) motility disorders and inflammatory bowel disease (IBD). These disorders affect more than 15 percent of the general population.
Led by Ali Rezaie, MD, a specialist in GI motility disorder and IBD, the Rezaie Lab studies issues including:
- Irritable Bowel Syndrome - Studying disturbances in large intestines (25 to 45 million Americans—of which about 66 percent are women—suffer from IBS)
- Microbiome - Uncovering the genetic material of bacteria, fungi, archaea and viruses affecting the GI tract
- Small Intestinal Bacterial Overgrowth - Looking for drug alternatives to treat excessive bacteria in the small intestine that inhibit digestion and absorption
- Biomarkers - Developing therapeutic interventions to combat symptoms and causes of GI motility disorders and IBD
- Alternatives to Antibiotics - Finding new treatments independent of antibiotics
The Rezaie Laboratory is affiliated with the Cedars-Sinai Department of Medicine and GI Motility Program.
Individualized prescription based on microbiome characteristics—a semipersonalized treatment approach based on microbiome. The Rezaie Lab continues to focus on creating a completely personalized treatment.